Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Hikma Pharmaceuticals in discussions to buy GSK assets in Egypt and Tunisia

Published 26/01/2021, 11:39
Updated 26/01/2021, 11:41
© Reuters.

© Reuters.

By Samuel Indyk

Investing.com – Hikma Pharmaceuticals PLC (LON:HIK) confirmed on Tuesday it is in discussions with GlaxoSmithKline PLC (LON:GSK) to purchase certain assets in Egypt and Tunisia. GlaxoSmithKline S.A.E., the listed Egyptian subsidiary of GlaxoSmithKline, first made an announcement to the Egyptian Exchange regarding the potential deal.

The assets in question are GSK’s pharmaceutical and manufacturing business in Egypt and their pharmaceutical business in Tunisia. No financial details of any deal have been disclosed at this stage and Hikma announced they expect to do due diligence on the assets, the results of which will form the basis for further discussions with GSK in connection with the proposed transaction.

Hikma also said the proposed transaction is subject to a number of conditions and as such there can be no guarantee at this stage that the deal will progress.

At 11:35GMT, FTSE 100 component Hikma Pharmaceuticals’ shares were up 1.3% at £25.27. GlaxoSmithKline’s shares were trading higher by 1.00% at £14.19.  

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.